Mural Oncology plc (MURA)
NASDAQ: MURA · Real-Time Price · USD
2.610
-0.030 (-1.14%)
Apr 25, 2025, 11:59 AM EDT - Market open
Mural Oncology Employees
Mural Oncology had 116 employees as of December 31, 2024. The number of employees decreased by 1 or -0.85% compared to the previous year.
Employees
116
Change (1Y)
-1
Growth (1Y)
-0.85%
Revenue / Employee
n/a
Profits / Employee
-$1,107,879
Market Cap
44.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 116 | -1 | -0.85% |
| Dec 31, 2023 | 117 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
MURA News
- 10 days ago - Mural Oncology Announces Plans to Explore Strategic Alternatives - GlobeNewsWire
- 4 weeks ago - Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges - Benzinga
- 4 weeks ago - Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 6 weeks ago - Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - GlobeNewsWire
- 2 months ago - Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts - GlobeNewsWire
- 5 months ago - Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer - GlobeNewsWire